The Latin America, Middle East and Africa Antiplatelet Market would witness market growth of 6.9% CAGR during the forecast period (2023-2030). In the year 2026, the LAMEA market's volume is expected to surge to 36.5 million Units, showcasing a growth of 8.0% (2023-2030).
Antithrombotic is a substance that aids in preventing thrombus formation. Different antithrombotic agents, such as antiplatelet pharmaceuticals, anticoagulants, and thrombolytics, affect distinct blood clotting processes. The primary use of it is to address the body's irregular blood flow. Inactivity, blood vessel injury, medical and genetic conditions, pregnancy, obesity, and smoking primarily cause thrombosis. The demand for life-saving drugs will certainly increase with a developing regional population.
Public awareness campaigns and improved medical screening practices have led to the earlier detection of cardiovascular risk factors. This, in turn, has increased the number of individuals prescribed antiplatelet drugs as part of preventive strategies. Some antiplatelet drugs are combined with other medications, such as anticoagulants or statins, to provide a more comprehensive approach to cardiovascular care. The development and use of combination therapies can further boost the market. The market also expands in emerging economies as healthcare infrastructure improves and access to medical care becomes more widespread. This trend is driven by both the increasing incidence of cardiovascular diseases and greater access to healthcare services.
The demand for antiplatelet drugs in the LAMEA region is closely tied to the increasing prevalence of CVDs and the efforts to improve cardiovascular care and healthcare infrastructure. As the region continues to expand and urbanize, addressing the cardiovascular disease burden and ensuring access to effective treatments, including antiplatelet therapies, will remain significant public health priorities. These factors will aid in the expansion of the regional market.
The Brazil market dominated the LAMEA Antiplatelet Market by Country in 2022 and would continue to be a dominant market till 2030; thereby, achieving a market value of $78.1 Million by 2030. The Argentina market is registering a CAGR of 7.5% during (2023 - 2030). Additionally, The UAE market would witness a CAGR of 6.7% during (2023 - 2030).
Based on Route of Administration, the market is segmented into Oral, and Injectable. Based on Drug Class, the market is segmented into Adenosine diphosphate (ADP) Receptor Inhibitors, Irreversible Inhibitors Cyclooxygenase, and Others. Based on Distribution Channel, the market is segmented into Drug store & Retail Pharmacies, Hospital Pharmacies, and Online Providers. Based on countries, the market is segmented into Brazil, Argentina, UAE, Saudi Arabia, South Africa, Nigeria, and Rest of LAMEA.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Cipla Limited, Glenmark Pharmaceuticals Limited, Bayer AG, AstraZeneca PLC, Daiichi Sankyo Company, Limited, Eli Lilly And Company, Otsuka Pharmaceutical Co., Ltd., Sanofi S.A. , Lupin Limited and Chiesi Farmaceutici S.p.A.
Antithrombotic is a substance that aids in preventing thrombus formation. Different antithrombotic agents, such as antiplatelet pharmaceuticals, anticoagulants, and thrombolytics, affect distinct blood clotting processes. The primary use of it is to address the body's irregular blood flow. Inactivity, blood vessel injury, medical and genetic conditions, pregnancy, obesity, and smoking primarily cause thrombosis. The demand for life-saving drugs will certainly increase with a developing regional population.
Public awareness campaigns and improved medical screening practices have led to the earlier detection of cardiovascular risk factors. This, in turn, has increased the number of individuals prescribed antiplatelet drugs as part of preventive strategies. Some antiplatelet drugs are combined with other medications, such as anticoagulants or statins, to provide a more comprehensive approach to cardiovascular care. The development and use of combination therapies can further boost the market. The market also expands in emerging economies as healthcare infrastructure improves and access to medical care becomes more widespread. This trend is driven by both the increasing incidence of cardiovascular diseases and greater access to healthcare services.
The demand for antiplatelet drugs in the LAMEA region is closely tied to the increasing prevalence of CVDs and the efforts to improve cardiovascular care and healthcare infrastructure. As the region continues to expand and urbanize, addressing the cardiovascular disease burden and ensuring access to effective treatments, including antiplatelet therapies, will remain significant public health priorities. These factors will aid in the expansion of the regional market.
The Brazil market dominated the LAMEA Antiplatelet Market by Country in 2022 and would continue to be a dominant market till 2030; thereby, achieving a market value of $78.1 Million by 2030. The Argentina market is registering a CAGR of 7.5% during (2023 - 2030). Additionally, The UAE market would witness a CAGR of 6.7% during (2023 - 2030).
Based on Route of Administration, the market is segmented into Oral, and Injectable. Based on Drug Class, the market is segmented into Adenosine diphosphate (ADP) Receptor Inhibitors, Irreversible Inhibitors Cyclooxygenase, and Others. Based on Distribution Channel, the market is segmented into Drug store & Retail Pharmacies, Hospital Pharmacies, and Online Providers. Based on countries, the market is segmented into Brazil, Argentina, UAE, Saudi Arabia, South Africa, Nigeria, and Rest of LAMEA.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Cipla Limited, Glenmark Pharmaceuticals Limited, Bayer AG, AstraZeneca PLC, Daiichi Sankyo Company, Limited, Eli Lilly And Company, Otsuka Pharmaceutical Co., Ltd., Sanofi S.A. , Lupin Limited and Chiesi Farmaceutici S.p.A.
Scope of the Study
Market Segments Covered in the Report:
By Route of Administration (Volume, Million Units, USD Million, 2019-2030)- Oral
- Injectable
- Adenosine diphosphate (ADP) Receptor Inhibitors
- Irreversible Inhibitors Cyclooxygenase
- Others
- Drug store & Retail Pharmacies
- Hospital Pharmacies
- Online Providers
- Brazil
- Argentina
- UAE
- Saudi Arabia
- South Africa
- Nigeria
- Rest of LAMEA
Key Market Players
List of Companies Profiled in the Report:
- Cipla Limited
- Glenmark Pharmaceuticals Limited
- Bayer AG
- AstraZeneca PLC
- Daiichi Sankyo Company, Limited
- Eli Lilly And Company
- Otsuka Pharmaceutical Co., Ltd.
- Sanofi S.A.
- Lupin Limited
- Chiesi Farmaceutici S.p.A
Unique Offerings
- Exhaustive coverage
- The highest number of Market tables and figures
- Subscription-based model available
- Guaranteed best price
- Assured post sales research support with 10% customization free
Table of Contents
Chapter 1. Market Scope & Methodology
Chapter 2. Market At a Glance
Chapter 3. Market Overview
Chapter 4. LAMEA Antiplatelet Market by Route of Administration
Chapter 5. LAMEA Antiplatelet Market by Drug Class
Chapter 6. LAMEA Antiplatelet Market by Distribution Channel
Chapter 7. LAMEA Antiplatelet Market by Country
Chapter 8. Company Profiles
Companies Mentioned
- Cipla Limited
- Glenmark Pharmaceuticals Limited
- Bayer AG
- AstraZeneca PLC
- Daiichi Sankyo Company, Limited
- Eli Lilly And Company
- Otsuka Pharmaceutical Co., Ltd.
- Sanofi S.A.
- Lupin Limited
- Chiesi Farmaceutici S.p.A
Methodology
LOADING...
